Search

Your search keyword '"Dai Okazaki"' showing total 3 results
Start Over Author "Dai Okazaki" Journal bmc cancer
3 results on '"Dai Okazaki"'

1. Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial

Author

Natsuo Tomita, Hiromichi Ishiyama, Chiyoko Makita, Yukihiko Ohshima, Aiko Nagai, Fumiya Baba, Mayu Kuno, Shinya Otsuka, Takuhito Kondo, Chikao Sugie, Tatsuya Kawai, Taiki Takaoka, Dai Okazaki, Akira Torii, Masanari Niwa, Nozomi Kita, Seiya Takano, Shogo Kawakami, Masayuki Matsuo, Tomoyasu Kumano, Makoto Ito, Sou Adachi, Souichiro Abe, Takayuki Murao, and Akio Hiwatashi

Subjects
Brain metastases, Radiation biology, Stereotactic radiation, Treatment outcome, Clinical Trial, Phase II, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Radiobiological daily changes within tumors are considered to be quite different between stereotactic radiotherapy (SRT) (e.g., 50 Gy in 4 fractions) and conventional radiotherapy (e.g., 60 Gy in 30 fractions). We aim to assess the optimal interval of irradiation in SRT and compare outcomes of daily irradiation with irradiation at two- to three-day intervals in SRT for patients with one to five brain metastases (BM). Methods This study is conducted as a multicenter open-label randomized phase II trial. Patients aged 20 or older with one to five BM, less than 3.0 cm diameter, and Karnofsky Performance Status ≥70 are eligible. A total of 70 eligible patients will be enrolled. After stratifying by the number of BMs (1, 2 vs. 3–5) and diameter of the largest tumor (

Published
2022
Full Text
View/download PDF

2. The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments

Author

Mariko Kawamura, Yutaro Koide, Taro Murai, Shunichi Ishihara, Yuuki Takase, Takayuki Murao, Dai Okazaki, Takahiro Yamaguchi, Kaoru Uchiyama, Yoshiyuki Itoh, Takeshi Kodaira, Yuta Shibamoto, Mika Mizuno, Fumitaka Kikkawa, and Shinji Naganawa

Subjects
Small cell carcinoma, Cervical cancer, Rare cancer, Chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Standard treatments for small cell carcinoma of the cervix (SCCC) have not been established. In this study, we aimed to estimate the optimal treatment strategy for SCCC. Methods This was a multicenter retrospective study. Medical records of patients with pathologically proven SCCC treated between 2003 and 2016 were retrospectively analyzed. Overall survival (OS) was plotted using the Kaplan-Meier method. Log-rank tests and Cox regression analysis were used to assess the differences in survival according to stage, treatment strategy, and chemotherapy regimen. Results Data of 78 patients were collected, and after excluding patients without immunohistopathological staining, 65 patients were evaluated. The median age of the included patients was 47 (range: 24–83) years. The numbers of patients with International Federation of Gynecology and Obstetrics (FIGO) 2018 stages I-IIA, IIB-IVA, IVB were 23 (35%), 34 (52%), and 8 (12%), respectively. Of 53 patients who had undergone chemotherapy, 35 and 18 received SCCC and non-SCCC regimens as their first-line chemotherapy regimen, respectively. The 5-year OS for all patients was 49%, while for patients with FIGO stages I-IIA, IIB-IVA, IVB, it was 60, 50, and 0%, respectively. The 5-year OS rates for patients who underwent treatment with SCCC versus non-SCCC regimens were 59 and 13% (p

Published
2021
Full Text
View/download PDF

3. The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments

Author

Fumitaka Kikkawa, Takayuki Murao, Shunichi Ishihara, Dai Okazaki, Yoshiyuki Itoh, Kaoru Uchiyama, Takeshi Kodaira, Takahiro Yamaguchi, Taro Murai, Yuuki Takase, Shinji Naganawa, Mariko Kawamura, Mika Mizuno, Yuta Shibamoto, and Yutaro Koide

Subjects
Adult, Cancer Research, medicine.medical_specialty, Uterine Cervical Neoplasms, Antineoplastic Agents, Kaplan-Meier Estimate, Small-cell carcinoma, Young Adult, Japan, Internal medicine, Cause of Death, Genetics, medicine, Humans, Chemotherapy, Stage (cooking), Carcinoma, Small Cell, Cervix, RC254-282, Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Cervical cancer, Aged, 80 and over, Small cell carcinoma, Proportional hazards model, business.industry, Rare cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Retrospective cohort study, Chemoradiotherapy, Middle Aged, medicine.disease, Chemotherapy regimen, Neoadjuvant Therapy, Regimen, medicine.anatomical_structure, Oncology, Female, business
Abstract

Background Standard treatments for small cell carcinoma of the cervix (SCCC) have not been established. In this study, we aimed to estimate the optimal treatment strategy for SCCC. Methods This was a multicenter retrospective study. Medical records of patients with pathologically proven SCCC treated between 2003 and 2016 were retrospectively analyzed. Overall survival (OS) was plotted using the Kaplan-Meier method. Log-rank tests and Cox regression analysis were used to assess the differences in survival according to stage, treatment strategy, and chemotherapy regimen. Results Data of 78 patients were collected, and after excluding patients without immunohistopathological staining, 65 patients were evaluated. The median age of the included patients was 47 (range: 24–83) years. The numbers of patients with International Federation of Gynecology and Obstetrics (FIGO) 2018 stages I-IIA, IIB-IVA, IVB were 23 (35%), 34 (52%), and 8 (12%), respectively. Of 53 patients who had undergone chemotherapy, 35 and 18 received SCCC and non-SCCC regimens as their first-line chemotherapy regimen, respectively. The 5-year OS for all patients was 49%, while for patients with FIGO stages I-IIA, IIB-IVA, IVB, it was 60, 50, and 0%, respectively. The 5-year OS rates for patients who underwent treatment with SCCC versus non-SCCC regimens were 59 and 13% (p Conclusion Our results suggest that the application of an SCCC regimen such as EP or IP as first-line chemotherapy for patients with locally advanced SCCC may play a key role in OS. These findings need to be validated in future nationwide, prospective clinical studies.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results